Cargando…
Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS(G12D) inhibitor MRTX1133
Mutations in KRAS are common drivers of human cancers and are often those with the poorest overall prognosis for patients. A recently developed compound, MRTX1133, has shown promise in inhibiting the activity of KRAS(G12D) mutant proteins, one of the main drivers in pancreatic cancer. To better unde...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cold Spring Harbor Laboratory
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10055375/ https://www.ncbi.nlm.nih.gov/pubmed/36993160 http://dx.doi.org/10.1101/2023.03.23.533981 |